Oak Associates Ltd. OH continued to hold its position in Merck & Co. (NYSE:MRK) during the second quarter, Holdings Channel reports. The institutional investor owned 55,800 shares of the company’s stock at the end of the second quarter. Oak Associates Ltd. OH’s holdings in Merck & Co. were worth $3,215,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Americafirst Capital Management LLC bought a new position in Merck & Co. during the second quarter valued at about $115,000. NewSquare Capital LLC increased its position in Merck & Co. by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock valued at $121,000 after buying an additional 261 shares during the last quarter. First New York Securities LLC NY bought a new position in Merck & Co. during the second quarter valued at about $121,000. QCI Asset Management Inc. NY increased its position in Merck & Co. by 1.1% in the second quarter. QCI Asset Management Inc. NY now owns 2,382 shares of the company’s stock valued at $137,000 after buying an additional 27 shares during the last quarter. Finally, Lowe fs LLC increased its position in Merck & Co. by 1.8% in the second quarter. Lowe fs LLC now owns 2,619 shares of the company’s stock valued at $151,000 after buying an additional 46 shares during the last quarter. Institutional investors own 72.93% of the company’s stock.
Shares of Merck & Co. (NYSE:MRK) opened at 62.09 on Wednesday. The firm has a 50-day moving average of $62.50 and a 200 day moving average of $58.90. The company has a market cap of $171.69 billion, a P/E ratio of 34.06 and a beta of 0.68. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.86.
Merck & Co. (NYSE:MRK) last announced its quarterly earnings results on Friday, July 29th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.02. The company had revenue of $9.84 billion for the quarter, compared to analyst estimates of $9.79 billion. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The firm’s revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.86 EPS. Equities analysts anticipate that Merck & Co. will post $3.75 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 15th were issued a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a dividend yield of 2.96%. The ex-dividend date of this dividend was Tuesday, September 13th. Merck & Co.’s dividend payout ratio (DPR) is presently 101.10%.
A number of research firms recently weighed in on MRK. Argus reissued a “buy” rating and issued a $65.00 target price on shares of Merck & Co. in a research note on Wednesday, September 14th. BMO Capital Markets reissued a “market perform” rating and issued a $62.00 target price on shares of Merck & Co. in a research note on Tuesday, August 2nd. Jefferies Group upped their target price on shares of Merck & Co. from $50.00 to $53.00 and gave the company a “hold” rating in a research note on Thursday, July 14th. Leerink Swann reissued a “hold” rating and issued a $58.00 target price on shares of Merck & Co. in a research note on Thursday, July 14th. Finally, Piper Jaffray Cos. reissued a “neutral” rating and issued a $62.00 target price (up previously from $58.00) on shares of Merck & Co. in a research note on Monday, August 8th. Thirteen analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of €65.58 ($72.06).
In related news, EVP Clark Golestani sold 3,000 shares of Merck & Co. stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of €63.03 ($69.26), for a total transaction of €189,090.00 ($207,791.21). The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Adam H. Schechter sold 39,200 shares of Merck & Co. stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of €62.61 ($68.80), for a total transaction of €2,454,312.00 ($2,697,046.15). Following the sale, the executive vice president now directly owns 39,200 shares in the company, valued at €2,454,312 ($2,697,046.15). The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.